Bioactivx
Singapore-based MedTech startup that 3D-prints Bioactiv Matrix, a synthetic, animal-free regenerative wound-care skin substitute, using a proprietary compounded filament and cleanroom FDM/FFF manufacturing process.
- Stage
- Early Stage
- Total Funding
- $4.9M
- Latest Round
- Venture Round
- Key Investors
- Cocoon Capital; Martin Krupp (ContInvest)
Technology & Products
Key Products
Bioactiv Matrix (flagship synthetic skin substitute); Bioactiv Foam; pipeline products include Bioactiv cellulose for wound packing, antimicrobial foam and cellulose, and a Bioactiv Surgical Wound Closure device.
Technological Advantage
In-house compounding of a proprietary active-ingredient filament combined with validated FDM/FFF print parameters and ISO 13485-certified cleanroom operations, enabling repeatable, on-demand, decentralized manufacturing on an open hardware platform (UltiMaker) rather than a closed materials ecosystem.
Differentiation
Value Proposition
A synthetic, animal-free regenerative skin substitute manufactured via a proprietary 3D-printed material-extrusion process, enabling on-demand production that does not require cold-chain storage.
How They Differentiate
Uses a proprietary in-house compounded active-ingredient filament on an open FDM/FFF platform to enable on-demand, decentralized, cold-chain-free manufacturing, versus centralized production models used by incumbent synthetic dermal matrix makers.
Market & Competition
Target Customers
Hospitals, burn units, and wound care clinics treating acute and chronic wounds (burns, ulcers, cuts, abrasions); plastic, reconstructive, and vascular surgeons for clinical trial partnerships.
Industry Verticals
Medical/Healthcare - wound care and regenerative medicine
Competitors
PolyNovo (NovoSorb BTM synthetic polyurethane dermal matrix, FDA-cleared, ~A$150M FY26 revenue); traditional collagen-based skin substitutes and donor skin grafts.
Growth & Milestones
Major Milestones
2023: Founded as A*STAR/SingHealth spin-off. Nov 2025: Raised $1.425M seed round led by Cocoon Capital; opened Singapore manufacturing facility built to ISO 13485 standards. Aug 2026: Raised $3M pre-Series A co-led by Cocoon Capital and Martin Krupp, taking cumulative funding to $4.9M; submitted full Bioactiv Matrix data package to Singapore's HSA, targeting Q4 2026 approval; signed MOU with UltiMaker for a scalable 3D-printed wound care manufacturing system; FDA submission planned 2026, EU MDR submission planned 2027.